Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 17, 2013, Pages 7009-7013

  Kikuta, Junichi ^a,b   Kawamura, Shunsuke ^a,b   Okiji, Fumie ^a,b   Shirazaki, Mai ^a,b   Sakai, Sadaoki ^c   Saito, Hitoshi ^c   Ishii, Masaru ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Chemotaxis; Circulation; Imaging; Immunology; Treatment

Indexed keywords

CALCITRIOL; ELDECALCITOL; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; CELL MIGRATION; DRUG ACTIVITY; MONOCYTE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRECURSOR MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84876864069     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218799110     Document Type: Article

References (39)

1. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289(5484):1504-1508.
2. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4(8):638-649.
3. Karsenty G, Wagner EF (2002) Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2(4):389-406.
4. Ishii M, et al. (2009) Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458(7237):524-528.
5. Klauschen F, et al. (2009) Quantifying cellular interaction dynamics in 3D fluorescence microscopy data. Nat Protoc 4(9):1305-1311.
6. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN (2010) Chemo-repulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 207(13):2793-2798.
7. Okamoto H, et al. (2000) Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol 20(24):9247-9261.
8. Russell RG, et al. (2007) Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209-257.
9. Bone HG, et al. (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res 25(5):937-947.
10. Eisman JA, et al. (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 26(2):242-251.
11. Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16(2):200-257.
12. Plum LA, DeLuca HF (2010) Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9(12):941-955.
13. Roodman GD, Ibbotson KJ, MacDonald BR, Kuehl TJ, Mundy GR (1985) 1, 25-Dihy-droxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci USA 82(23): 8213-8217.
14. Yasuda H, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprote-gerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95(7):3597-3602.
15. Suda T, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20(3): 345-357.
16. Suda T, Ueno Y, Fujii K, Shinki T (2003) Vitamin D and bone. J Cell Biochem 88(2): 259-266.
17. Suda T, Takahashi F, Takahashi N (2012) Bone effects of vitamin D-Discrepancies between in vivo and in vitro studies. Arch Biochem Biophys 523(1):22-29.
18. Ishii M, et al. (2006) RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J Bone Miner Res 21(6):965-976.
19. Maeda Y, Seki N, Sato N, Sugahara K, Chiba K (2010) Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol 22(6):515-525.
20. Burnett SH, et al. (2004) Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J Leukoc Biol 75(4):612-623.
21. Jung S, et al. (2000) Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20(11): 4106-4114.
22. Koizumi K, et al. (2009) Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol 183(12):7825-7831.
23. Takasu H, et al. (2006) c-Fos protein as a target of anti- osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 116(2):528-535.
24. Harada S, et al. (2012) Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 27(2):461-473.
25. Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A (2012) Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 50(5):1054-1063.
26. Sugimoto M, Futaki N, Harada M, Kaku S (2013) Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histo-morphometry in ovariectomized rats: A comparison with alfacalcidol and alendro-nate. Bone 52(1):181-188.
27. Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27(5):425-434.
28. Matsumoto T, et al. (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90(9):5031-5036.
29. Sanford M, McCormack PL (2011) Eldecalcitol: A review of its use in the treatment of osteoporosis. Drugs 71(13):1755-1770.
30. Matsumoto T, et al. (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone 49(4):605-612.
31. Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T (2011) Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 49(3):328-334.
32. Okano T, et al. (1991) A novel synthetic vitamin D3 analogue, 2-beta-(3-hydrox-ypropoxy)-calcitriol (ED-71): Its biological activities and pharmacological effects on calcium metabolism. Contrib Nephrol 91:116-122.
33. Fukuhara S, et al. (2012) The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 122(4): 1416-1426.
34. Lee SH, et al. (2012) Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans. J Clin Endocrinol Metab 97(8):E1421-E1428.
35. Bouillon R, et al. (2008) Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 29(6):726-776.
36. Vuolo L, Di Somma C, Faggiano A, Colao A (2012) Vitamin D and cancer. Front En-docrinol (Lausanne) 3:58.
37. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13(3): 100-105.
38. Rosen H, Goetzl EJ (2005) Sphingosine 1-phosphate and its receptors: An autocrine and paracrine network. Nat Rev Immunol 5(7):560-570.
39. Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127-159.